<DOC>
	<DOCNO>NCT02826070</DOCNO>
	<brief_summary>The purpose study demonstrate long-term treatment ( six year ) telbivudine telbivudine plus adefovir result regression liver inflammation fibrosis/cirrhosis .</brief_summary>
	<brief_title>EFFORT Further Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>1 . Patients complete EFFORT extension study . 2 . Patients baseline ( week 0 EFFORT study ) HBV DNA &lt; 9 Log copies/mL ALT ≥2×ULN . 3 . Patients willing participate extension study . 4 . Patient willing able comply study drug regimen study requirement . 5 . Patients must give write informed consent assessment perform . 1 . Poor compliance judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>